Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. New issue in AttgeNO
Mandate

New issue in AttgeNO

May 02, 2018

The Swedish pharmaceutical research company AttgeNO has performed a new issue of shares.

AttgeNO works on the development of new pharmaceuticals which expand blood vessels. Supernitro (PDNO) is a new, patented pharmaceutical candidate for treatment of acute and life-threatening high blood pressure in the lungs, which, can arise for example in connection with heart surgery and may result in death. The capital generated as a result of the new issue of shares is intended to give AttgeNO an opportunity to perform clinical Phase 1 studies during 2019.

AttgeNO was advised by partner Johan Winnerblad.

New partners and counsels appointed at Vinge’s Stockholm office

 Advokat Sofie Bjärtun, advokat Rikard Lindahl, advokat Malin Malm Waerme and advokat Daniel Wendelsson at Vinge’s Stockholm office have been appointed as new partners as of 1 January 2022. The following lawyers have been elected as counsels at Vinge’s Stockholm office: Advokat Stojan Arnerstål, advokat Amanda Knutsson, advokat Jolene Reimerson, advokat Linnéa Sellström and advokat Filip Öhrner.
July 06, 2021

EU climate taxonomy – New regulations concerning companies’ publication of information

According to the European Union’s climate taxonomy, certain organisations must publish to what extent their operations are environmentally sustainable. In order to clarify what information the companies need to report, as well as how this should be done, the EU Commission has prepared a new delegated regulation. Primarily, the delegated regulation establishes relevant financial key ratios and different report precedents.
June 21, 2021

What an employer should know about the New Whistleblowing Act

Why adopt a new Whistleblowing Act when the current act was adopted as late as 2017?
June 15, 2021